NASDAQ:ENTA

Enanta Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ENTA

*Your capital is at risk

$11.24

-0.790 (-6.57%)

At Close: Jun 03, 2026

Enanta Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 88.69. In total, the insiders bought 1.39M and sold 42.79K ENTA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	88.69
● Buy	1.39M shares
● Sell	42.79K shares
77% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Aug 26, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 88.69. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 26, 2025 Buy	Common Stock	Trout Harry R. Iii Vice President, Finance	CEO / President	0 Value: $0
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	5 513 Value: $48.7K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	5 250 Value: $47.2K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	3 482 Value: $156.7K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	4 914 Value: $370.2K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	5 402 Value: $235.4K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	8 125 Value: $514.7K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	7 000 Value: $568.4K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	5 950 Value: $288.7K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	2 668 Value: $80.0K
Aug 26, 2025 Buy	Stock Option (right to buy)	Capps Kathleen S. See Remarks	Officer	497 Value: $14.8K
Aug 26, 2025 Buy	Common Stock	Capps Kathleen S. See Remarks	Officer	0 Value: $0
Aug 08, 2025 Sell	Common Stock F-InKind	Rottinghaus Scott T. Chief Medical Officer	Officer	2 217 Value: $15.5K
Aug 08, 2025 Sell	Common Stock F-InKind	Rottinghaus Scott T. Chief Medical Officer	Officer	2 217 Value: $15.5K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Vance Terry Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Russell Lesley Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Peterson Kristine Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Hata Yujiro S Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Foletta Mark G Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Carter Bruce L A Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Carter Bruce L A Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Foletta Mark G Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Hata Yujiro S Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Peterson Kristine Director	Director	15 700 Value: $107.2K
Mar 13, 2025 Buy	Stock Option (right to buy) A-Award	Russell Lesley Director	Director	15 700 Value: $107.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ENANTA PHARMACEUTICALS

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A pro...

Read Full Profile Here